Skip to content

Released May 8, 2024, after the close

10-Q filed May 8, 2024, 38 days after period end · 0000950170-24-055680

Q1 2024 · 10-Q
Revenue$5.79M— vs Q1 2023−19.2% vs Q4 2023
Net Income-$9.08MN/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$1.66N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$10,729,000N/M
Operating Cash Flow-$18,364,000N/M
Free Cash Flowderived-$18,378,000N/M
Margins · derived
Operating margin-185.5%
Net margin-156.9%

What the release said

The release

Same quarter

MetricQ1 2024Q1 2023Q1 2022Q1 2021
Revenue$5.79M$0.00——
Net Income-$9.08M-$18.95M-$23.09M-$27.20M
EPS Diluted-$1.66-$4.46-$0.48-$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR